As of January 22, 2025, Y-mAbs Therapeutics (YMAB) has a market cap of $0.28 billion USD. According to our data, Y-mAbs Therapeutics is ranked No.6796 in global market value.
Year | Market Cap | %Change |
---|---|---|
Jan 22, 2025 | $0.28 B |
-20.95%
|
Dec 31, 2024 | $0.35 B |
14.81%
|
Dec 29, 2023 | $0.31 B |
39.75%
|
Dec 30, 2022 | $0.22 B |
-69.90%
|
Dec 31, 2021 | $0.73 B |
-67.26%
|
Dec 31, 2020 | $2.22 B |
58.43%
|
Dec 31, 2019 | $1.40 B |
53.64%
|
Dec 31, 2018 | $0.91 B |
100%
|
Name | Market Cap | Market cap difference | Regions |
---|---|---|---|
United Therapeutics
UTHR
|
$16.58 B |
-0.000 M
|
USA
|
MacroGenics
MGNX
|
$0.19 B |
-0.000 M
|
USA
|
Adaptimmune Therapeutics
ADAP
|
$0.15 B |
0.000 M
|
UK
|
Iovance Biotherapeutics
IOVA
|
$1.83 B |
-0.000 M
|
USA
|
Fate Therapeutics
FATE
|
$0.15 B |
0.000 M
|
USA
|
bluebird bio
BLUE
|
$76.22 M |
0.000 M
|
USA
|
Cellectis
CLLS
|
$0.16 B |
4.659 M
|
France
|
Allogene Therapeutics
ALLO
|
$0.40 B |
0.000 M
|
USA
|
Atara Biotherapeutics
ATRA
|
$39.68 M |
0.000 M
|
USA
|
Autolus Therapeutics
AUTL
|
$0.57 B |
0.000 M
|
UK
|
Market Cap | = | YMAB Stock Price | * | YMAB Shares Outstanding |
= | $6.19 | * | 44.79 M | |
= | $0.28 B |